The global viral vector manufacturing market was valued at USD 1,469.6 Million in 2024 and is projected to reach USD 8,512.2 Million by 2033, exhibiting a CAGR of 21.6% during the forecast period of 2025-2033. Growth is driven by rising genetic disorders, increased gene therapy adoption, advances in biotechnology, expanding clinical trials, government funding, and strong R&D investments. North America dominates the market, supported by its advanced biotech infrastructure and leading pharmaceutical companies.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Viral Vector Manufacturing Market Key Takeaways
- Current Market Size: USD 1,469.6 Million in 2024
- CAGR: 21.6% (2025-2033)
- Forecast Period: 2025-2033
- North America held over 49.3% market share in 2024.
- The U.S. accounts for 91.90% of the total market share, driven by high prevalence of genetic disorders and cancers and strong government investment.
- FDA had approved 36 gene therapies as of March 2024, with more than 500 in development.
- Technological advancements like HEK293 cell line by Samsung Biologics increased viral vector yield by 25% in 2022.
- Manufacturing scale-up challenges are addressed by regulatory bodies such as FDA and EMA engaging with industry stakeholders.
Sample Request Link:
https://www.imarcgroup.com/viral-vector-manufacturing-market/requestsample
Market Growth Factors
The global viral vector manufacturing market is significantly propelled by the increasing prevalence of genetic disorders, infectious diseases, and cancer. The adoption of gene therapies using viral vectors, particularly for rare diseases, cancer, and neurological disorders, is expanding rapidly. Rising government funding and robust R&D investments globally are accelerating clinical trials, enhancing biotechnology infrastructure, and increasing market demand. These factors collectively support the market’s projected CAGR of 21.6% from 2025 to 2033.
Increased regulatory approvals and growing trust in the safety and efficacy profiles of gene therapies are boosting market confidence. As of March 18, 2024, the FDA approved 36 gene therapies, and over 500 gene therapy products are in development. The FDA anticipates annual approvals of 10 to 20 gene therapy products by 2025. This proactive regulatory environment, combined with industry investments in manufacturing infrastructure, is critical to scaling viral vector production and ensuring adequate supply for broad patient access.
Technological advancements such as the development of stable packaging cell lines and automation are enhancing production efficiency and scalability. For example, Samsung Biologics’ adoption of the HEK293 cell line technology resulted in a 25% increase in viral vector yield in 2022. The integration of AI and automation lowers costs and simplifies scaling processes, which is essential to meet increased demand for clinical-grade viral vectors in gene therapy applications. Regulatory and manufacturing challenges, including lengthy approval timelines and quality control during scale-up, are being addressed through evolving regulatory guidelines by FDA and EMA.
Market Segmentation
By Type:
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Others
Adeno-associated viral (AAV) vectors are the largest segment in 2024, favored for their versatility, safety profile, low immune response, and effectiveness in targeted gene delivery. They play a significant role in treating genetic disorders such as spinal muscular atrophy (SMA) and inherited retinal diseases, with ongoing vector engineering improvements enhancing their therapeutic potential.
By Disease:
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Cancer holds approximately 37.6% market share in 2024. The adoption of viral vectors in gene therapies, oncolytic virotherapy, and immunotherapies like CAR-T cell therapies drives growth. Increasing cancer prevalence and investments in oncology research have enhanced demand for innovative treatments.
By Application:
- Gene Therapy
- Vaccinology
Gene therapy dominates with about 56.9% market share in 2024. The segment benefits from rising gene therapy adoption to address genetic disorders, cancers, and rare diseases. Advances in viral vector technology and regulatory approvals are key growth factors.
By End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Pharmaceutical and biopharmaceutical companies lead as primary end-users due to their role in gene and cell therapy development and commercialization. Research institutes contribute by fostering innovation and conducting preclinical studies, supported by collaborations and government funding.
By Region:
- Asia Pacific
- Europe
- North America
- Latin America
- Middle East and Africa
Regional Insights
North America is the dominant regional market, commanding over 49.3% share in 2024. This leadership is attributed to robust biotechnology infrastructure, a strong base of pharmaceutical companies, significant government funding, and rapid growth in clinical trials. The region’s advanced research and development ecosystem further propels innovation and market expansion.
Recent Developments & News
- November 2024: FUJIFILM Diosynth Biotechnologies expanded cell therapy manufacturing in Thousand Oaks, California, with a USD 200 million investment to increase viral vector and cell therapy production capacity.
- October 2024: Lonza finalized acquisition of a large biologics manufacturing site in Vacaville, US, from Roche, enhancing its commercial manufacturing capabilities.
- October 2024: FinVector opened its high-tech global gene therapy manufacturing facility, Finport, in Kuopio, producing viral vector-based drug substances.
- May 2024: Merck & Co Inc agreed to acquire Mirus Bio for USD 600 million, expanding its viral vector manufacturing and transfection reagent offerings.
- March 2024: Oxford Biomedica reported high demand for its CDMO services, signing multiple agreements for viral vector types including lentiviral and AAV-based gene therapies.
Key Players
- Aldevron LLC
- Catalent, Inc
- Charles River Laboratories International Inc.
- Cytiva (Danaher Corporation)
- F. Hoffmann-La Roche Ltd
- FUJIFILM Diosynth Biotechnologies
- Genezen
- Kaneka Corporation
- Lonza
- Merck KGaA
- Oxford Biomedica PLC
- Thermo Fisher Scientific Inc.
Get Custom Market Research Report for Your Business:
https://www.imarcgroup.com/request?type=report&id=5016&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
